Pramlintide

DB01278

small molecule approved investigational

Deskripsi

Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.

Struktur Molekul 2D

Berat 3949.44
Wujud liquid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Approximately 48 minutes
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

The absolute bioavailability of a single subcutaneous dose of pramlintide is approximately 30 to 40%.

Metabolisme

Metabolized primarily by the kidneys.

Rute Eliminasi

Pramlintide is metabolized primarily by the kidneys.

Interaksi Makanan

1 Data
  • 1. Avoid alcohol. Ingesting alcohol may increase the risk of hypoglycemia.

Interaksi Obat

704 Data
Pegvisomant The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pramlintide.
Insulin human Pramlintide may increase the hypoglycemic activities of Insulin human.
Insulin lispro Pramlintide may increase the hypoglycemic activities of Insulin lispro.
Insulin glargine Pramlintide may increase the hypoglycemic activities of Insulin glargine.
Insulin pork Pramlintide may increase the hypoglycemic activities of Insulin pork.
Insulin aspart Pramlintide may increase the hypoglycemic activities of Insulin aspart.
Insulin detemir Pramlintide may increase the hypoglycemic activities of Insulin detemir.
Insulin glulisine Pramlintide may increase the hypoglycemic activities of Insulin glulisine.
NN344 Pramlintide may increase the hypoglycemic activities of NN344.
Insulin beef Pramlintide may increase the hypoglycemic activities of Insulin beef.
Insulin degludec Pramlintide may increase the hypoglycemic activities of Insulin degludec.
Insulin peglispro Pramlintide may increase the hypoglycemic activities of Insulin peglispro.
Insulin tregopil Pramlintide may increase the hypoglycemic activities of Insulin tregopil.
Insulin argine Pramlintide may increase the hypoglycemic activities of Insulin argine.
Tramadol The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Tramadol.
Trospium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Trospium.
Oxyphenonium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Oxyphenonium.
Benzatropine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Benzatropine.
Ziprasidone The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Ziprasidone.
Disopyramide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Disopyramide.
Amitriptyline The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Amitriptyline.
Ipratropium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Ipratropium.
Olanzapine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Olanzapine.
Metixene The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Metixene.
Terfenadine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Terfenadine.
Buclizine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Buclizine.
Clozapine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Clozapine.
Doxylamine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Doxylamine.
Trihexyphenidyl The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Trihexyphenidyl.
Oxyphencyclimine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Oxyphencyclimine.
Procyclidine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Procyclidine.
Profenamine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Profenamine.
Promazine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Promazine.
Hyoscyamine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Hyoscyamine.
Cyproheptadine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Cyproheptadine.
Imipramine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Imipramine.
Methscopolamine bromide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Methscopolamine bromide.
Chlorpromazine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Chlorpromazine.
Gallamine triethiodide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Gallamine triethiodide.
Darifenacin The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Darifenacin.
Tridihexethyl The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Tridihexethyl.
Triflupromazine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Triflupromazine.
Anisotropine methylbromide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Anisotropine methylbromide.
Nortriptyline The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Nortriptyline.
Amoxapine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Amoxapine.
Atropine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Atropine.
Nicardipine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Nicardipine.
Pirenzepine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Pirenzepine.
Paroxetine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Paroxetine.
Homatropine methylbromide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Homatropine methylbromide.
Rocuronium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Rocuronium.
Scopolamine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Scopolamine.
Benzquinamide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Benzquinamide.
Clidinium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Clidinium.
Propiomazine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Propiomazine.
Propantheline The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Propantheline.
Dicyclomine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Dicyclomine.
Biperiden The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Biperiden.
Brompheniramine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Brompheniramine.
Flupentixol The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Flupentixol.
Cocaine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Cocaine.
Quinidine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Quinidine.
Maprotiline The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Maprotiline.
Methantheline The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Methantheline.
Cycrimine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Cycrimine.
Glycopyrronium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Glycopyrronium.
Tolterodine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Tolterodine.
Oxybutynin The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Oxybutynin.
Promethazine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Promethazine.
Diphenhydramine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Diphenhydramine.
Doxacurium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Doxacurium.
Doxepin The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Doxepin.
Flavoxate The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Flavoxate.
Desipramine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Desipramine.
Orphenadrine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Orphenadrine.
Escitalopram The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Escitalopram.
Quetiapine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Quetiapine.
Mivacurium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Mivacurium.
Diphenidol The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Diphenidol.
Aripiprazole The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Aripiprazole.
Chlorprothixene The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Chlorprothixene.
Metocurine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Metocurine.
Pancuronium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Pancuronium.
Pipecuronium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Pipecuronium.
Methotrimeprazine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Methotrimeprazine.
Tiotropium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Tiotropium.
Solifenacin The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Solifenacin.
Isopropamide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Isopropamide.
Rapacuronium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Rapacuronium.
Mepenzolate The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Mepenzolate.
Pizotifen The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Pizotifen.
Fesoterodine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Fesoterodine.
Hexocyclium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Hexocyclium.
Dimetindene The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Dimetindene.
Aclidinium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Aclidinium.
Dexetimide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Dexetimide.
Benactyzine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Benactyzine.
Umeclidinium The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Umeclidinium.
Trimebutine The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Trimebutine.
Dosulepin The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Dosulepin.

Target Protein

Glucagon-like peptide 1 receptor GLP1R
Calcitonin receptor CALCR
Receptor activity-modifying protein 1 RAMP1
Receptor activity-modifying protein 2 RAMP2
Receptor activity-modifying protein 3 RAMP3

Referensi & Sumber

Synthesis reference: Andreas Brunner, Oleg Werbitzky, Stephane Varray, Francesca Quattrini, Holger Hermann, Andrew Strong, Fernando Albericio, Judit Tulla-Puche, Yesica Garcia Ramos, "PROCESS FOR THE PRODUCTION OF PRAMLINTIDE." U.S. Patent US20100249370, issued September 30, 2010.
Artikel (PubMed)
  • PMID: 17619527
    Jones MC: Therapies for diabetes: pramlintide and exenatide. Am Fam Physician. 2007 Jun 15;75(12):1831-5.
  • PMID: 16330288
    Ryan GJ, Jobe LJ, Martin R: Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2005 Oct;27(10):1500-12.
  • PMID: 18998755
    Edelman S, Maier H, Wilhelm K: Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008;22(6):375-86. doi: 10.2165/0063030-200822060-00004.
  • PMID: 12841822
    Kleppinger EL, Vivian EM: Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother. 2003 Jul-Aug;37(7-8):1082-9.

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Symlin
    Injection • 600 ug/1mL • Subcutaneous • US • Approved
  • Symlin
    Injection • 0.6 mg/1mL • Subcutaneous • US • Approved
  • SymlinPen
    Injection • 1000 ug/1mL • Subcutaneous • US • Approved
  • SymlinPen
    Injection • 1000 ug/1mL • Subcutaneous • US • Approved
  • SymlinPen
    Injection • 1000 ug/1mL • Subcutaneous • US • Approved
  • SymlinPen
    Injection • 1000 ug/1mL • Subcutaneous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul